Lenalidomide /lɛnəˈlɪdɵmaɪd/ (trade name Revlimid) is a derivative of thalidomide introduced in 2004.It was initially intended as a treatment for multiple myeloma for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS).
This page contains content from the copyrighted Wikipedia article "Lenalidomide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
